JAMES R. KLINENBERG, M.D.; STEPHEN E. GOLDFINGER, M.D.; J. EDWIN SEEGMILLER, M.D.
The clinical benefits derived from controlling the hyperuricemia of patients with gouty arthritis have been well-established (1, 2). This has been achieved by using uricosuric drugs to increase the renal excretion of uric acid, thereby lowering the serum urate concentration. Since the majority of patients with gout have evidence of some degree of overproduction of uric acid (3), another rational approach to therapy would be to decrease uric acid production. A decrease in purine biosynthesis in the human has been produced by the administration of the glutamine analogues 6-diazo-5 oxo-L-norleucine (DON) (4) and azaserine (5), which block an early stage
KLINENBERG JR, GOLDFINGER SE, SEEGMILLER JE. The Effectiveness of the Xanthine Oxidase Inhibitor Allopurinol in the Treatment of Gout. Ann Intern Med. 1965;62:639–647. doi: 10.7326/0003-4819-62-4-639
Download citation file:
Published: Ann Intern Med. 1965;62(4):639-647.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use